Impact of Tafamidis on Echocardiographic Cardiac Function of Patients With Transthyretin Cardiac Amyloidosis
2023; Japanese Circulation Society; Volume: 87; Issue: 4 Linguagem: Inglês
10.1253/circj.cj-22-0683
ISSN1347-4820
AutoresYasushi Ichikawa, Eri Oota, Susumu Odajima, Masayuki Kintsu, Saki Todo, Kimikazu Takeuchi, Yuki Yamauchi, Hiroaki Shiraki, Kentaro Yamashita, Terunobu Fukuda, Eriko Hisamatsu, Ken‐ichi Hirata, Hidekazu Tanaka,
Tópico(s)Peptidase Inhibition and Analysis
ResumoThe efficacy of a therapy for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) has not been proven, but tafamidis has been associated with favorable outcomes. However, echocardiographic details of the association of tafamidis with cardiac morphology remain undetermined. Moreover, whether the efficacy of tafamidis varies with the degree of cardiac involvement remains unknown. Using echocardiography, this study investigated the impact of tafamidis on the cardiac morphology of patients with ATTR-CM.
Referência(s)